This page has only limited features, please log in for full access.
Obesity or overweight are not superficial problems, constituting a pressing issue. The obesity index has almost tripled since 1975, which is an alarming state. Most of the individuals are currently becoming overweight or have inappropriate body mass index (BMI) conditions. Obesity is characterized by increased fat accumulation and thus poses a higher health risk. There is increased size and volume of fat cells in the body, which usually accounts for obesity. Many investigations have been carried out in this area, such as behavioral improvements, dietary changes, chemical involvements, etc., but presently no such goals are established to manage these health concerns. Based on previous literature reports and our interpretation, the current review indicates the involvement of various transcriptional and transporter functions in modifying the above-mentioned health conditions. Various transcriptional factors such as Forkhead box O1 (FoxO1) impart a significant effect on the physiology and pathology of metabolic dysfunction such as obesity. FoxO1 plays a dual role whether in the progression or suppression of metabolic processes depending on its targets. Thus, in the current study, will be discussed the dual role of FoxO1 in metabolic conditions (such as obesity), also summarizing the role of various other transcriptional factors involved in obesity.
Tapan Behl; Ishnoor Kaur; Aayush Sehgal; Sukhbir Singh; Gokhan Zengin; Nicoleta Negrut; Delia Nistor-Cseppento; Flavia Pavel; Raluca Corb Aron; Simona Bungau. Exploring the Genetic Conception of Obesity via the Dual Role of FoxO. International Journal of Molecular Sciences 2021, 22, 3179 .
AMA StyleTapan Behl, Ishnoor Kaur, Aayush Sehgal, Sukhbir Singh, Gokhan Zengin, Nicoleta Negrut, Delia Nistor-Cseppento, Flavia Pavel, Raluca Corb Aron, Simona Bungau. Exploring the Genetic Conception of Obesity via the Dual Role of FoxO. International Journal of Molecular Sciences. 2021; 22 (6):3179.
Chicago/Turabian StyleTapan Behl; Ishnoor Kaur; Aayush Sehgal; Sukhbir Singh; Gokhan Zengin; Nicoleta Negrut; Delia Nistor-Cseppento; Flavia Pavel; Raluca Corb Aron; Simona Bungau. 2021. "Exploring the Genetic Conception of Obesity via the Dual Role of FoxO." International Journal of Molecular Sciences 22, no. 6: 3179.
While the most common manifestations associated with rheumatoid arthritis (RA) are synovial damage and inflammation, the systemic effects of this autoimmune disorder are life-threatening, and are prevalent in 0.5–1% of the population, mainly associated with cardiovascular disorders (CVDs). Such effects have been instigated by an altered lipid profile in RA patients, which has been reported to correlate with CV risks. Altered lipid paradox is related to inflammatory burden in RA patients. The review highlights general lipid pathways (exogenous and endogenous), along with the changes in different forms of lipids and lipoproteins in RA conditions, which further contribute to elevated risks of CVDs like ischemic heart disease, atherosclerosis, myocardial infarction etc. The authors provide a deep insight on altered levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) in RA patients and their consequence on the cardiovascular health of the patient. This is followed by a detailed description of the impact of anti-rheumatoid therapy on the lipid profile in RA patients, comprising DMARDs, corticosteroids, anti-TNF agents, anti-IL-6 agents, JAK inhibitors and statins. Furthermore, this review elaborates on the prospects to be considered to optimize future investigation on management of RA and treatment therapies targeting altered lipid paradigms in patients.
Tapan Behl; Ishnoor Kaur; Aayush Sehgal; Gokhan Zengin; Ciprian Brisc; Mihaela Cristina Brisc; Mihai Alexandru Munteanu; Delia Carmen Nistor-Cseppento; Simona Bungau. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. International Journal of Molecular Sciences 2020, 21, 9505 .
AMA StyleTapan Behl, Ishnoor Kaur, Aayush Sehgal, Gokhan Zengin, Ciprian Brisc, Mihaela Cristina Brisc, Mihai Alexandru Munteanu, Delia Carmen Nistor-Cseppento, Simona Bungau. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. International Journal of Molecular Sciences. 2020; 21 (24):9505.
Chicago/Turabian StyleTapan Behl; Ishnoor Kaur; Aayush Sehgal; Gokhan Zengin; Ciprian Brisc; Mihaela Cristina Brisc; Mihai Alexandru Munteanu; Delia Carmen Nistor-Cseppento; Simona Bungau. 2020. "The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients." International Journal of Molecular Sciences 21, no. 24: 9505.
Clostridioides difficile (CD) is responsible for nosocomial diarrhea syndrome with possible severe progression. Recurrence of the disease induces higher health system costs, as well as exposes patients to additional health risks. Patients with recurrence of this disease are difficult to identify, so the purpose of this study is to quantify various demographic, clinical, and treatment factors that could prevent further progression to recurrence of the disease. In the period 2018–2019, about 195 patients were diagnosed with more than one episode of CDI in the three months following the first episode. The recurrence rate for CDI was 53.84% (60.95% for one episode and 39.05% for multiple episodes). Most commonly afflicted were 60–69-year-old patients, or those with higher Charlson Comorbidity Index (CCI). Multiple analyses associated cardiovascular (odds ratios (OR) = 3.02, 95% confidence intervals (CI) = 1.23–7.39, p = 0.015), digestive (OR = 3.58, 95% CI = 1.01–12.63, p = 0.047), dementia (OR = 3.26, 95% CI = 1.26–8.41, p = 0.014), immunosuppressive (OR = 3.88, 95% CI = 1.34–11.21, p = 0.012) comorbidities with recurrences. Risk factor identification in the first episode of CDI could lead to the implementation of treatment strategies to improve the patients’ quality of life affected by this disease.
Nicoleta Negrut; Simona Bungau; Tapan Behl; Shamim Khan; Cosmin Vesa; Cristiana Bustea; Delia Nistor-Cseppento; Marius Rus; Flavia-Maria Pavel; Delia Tit. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare 2020, 8, 352 .
AMA StyleNicoleta Negrut, Simona Bungau, Tapan Behl, Shamim Khan, Cosmin Vesa, Cristiana Bustea, Delia Nistor-Cseppento, Marius Rus, Flavia-Maria Pavel, Delia Tit. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare. 2020; 8 (3):352.
Chicago/Turabian StyleNicoleta Negrut; Simona Bungau; Tapan Behl; Shamim Khan; Cosmin Vesa; Cristiana Bustea; Delia Nistor-Cseppento; Marius Rus; Flavia-Maria Pavel; Delia Tit. 2020. "Risk Factors Associated with Recurrent Clostridioides difficile Infection." Healthcare 8, no. 3: 352.
Clostridium difficile infection (CDI) is the most common infectious disease related to antibiotic-associated diarrhoea and is a current leading cause of morbidity/mortality, with substantial consequences for healthcare services and overall public health. Thus, we performed a retrospective epidemiological study of CDI for a long period (8 years), in an infectious hospital located in north-western Romania, which serves an entire county of the country (617,827 inhabitants). From 2011 to 2018, 877 patients were diagnosed with CDI; the mean incidence of this disease was 2.76 cases/10,000 patient-days, with an increasing trend in the annual incidence until 2016, at which point there was a decrease. The most commonly afflicted were patients in the 75–84 age group, observed in winter and spring. The results show that the antibiotics were administered in 679 (77.42%) subjects, within the last 3 months before CDI, statistically significant more than proton-pump inhibitors (PPIs)—128 (14.60%) and antidepressant medications—60 (6.84%), which were administered during the same period (p < 0.001). No medication was reported in 10 (6.84%) cases of CDI, in the last 3 months of the study. The fatality rate attained 4.1%, tripling in 2018 vs. 2011. CDI became a significant public health conundrum that can, nevertheless, be combatted through a judicious use of antibiotics.
Nicoleta Negrut; Delia Carmen Nistor-Cseppento; Shamim Ahmad Khan; Carmen Pantis; Teodor Andrei Maghiar; Octavian Maghiar; Selim Aleya; Marius Rus; Delia Mirela Tit; Lotfi Aleya; Abbas Rahdar; Simona Bungau. Clostridium difficile Infection Epidemiology over a Period of 8 Years—A Single Centre Study. Sustainability 2020, 12, 4439 .
AMA StyleNicoleta Negrut, Delia Carmen Nistor-Cseppento, Shamim Ahmad Khan, Carmen Pantis, Teodor Andrei Maghiar, Octavian Maghiar, Selim Aleya, Marius Rus, Delia Mirela Tit, Lotfi Aleya, Abbas Rahdar, Simona Bungau. Clostridium difficile Infection Epidemiology over a Period of 8 Years—A Single Centre Study. Sustainability. 2020; 12 (11):4439.
Chicago/Turabian StyleNicoleta Negrut; Delia Carmen Nistor-Cseppento; Shamim Ahmad Khan; Carmen Pantis; Teodor Andrei Maghiar; Octavian Maghiar; Selim Aleya; Marius Rus; Delia Mirela Tit; Lotfi Aleya; Abbas Rahdar; Simona Bungau. 2020. "Clostridium difficile Infection Epidemiology over a Period of 8 Years—A Single Centre Study." Sustainability 12, no. 11: 4439.
Background and Objectives: This study evaluated the clinical characteristics of the acute coronary syndromes (ACS) in chronic kidney disease (CKD) patients and established prognostic values of the biomarkers and echocardiography. Materials and Methods: 273 patients admitted to the cardiology department of the Clinical County Emergency Hospital of Oradea, Romania, with ACS diagnosis were studied. Two study groups were formed according to the presence of CKD (137 patients with ACS + CKD and 136 with ACS without CKD). Kidney Disease: Improving Global Outcomes (KDIGO) threshold was used to assess the stages of CKD. Results: Data regarding the medical history, laboratory findings, biomarkers, echocardiography, and coronary angiography were analysed for both groups. ACS parameters were represented by ST-segment elevation myocardial infarction (STEMI), which revealed a greater incidence in subjects without CKD (43.88%); non-ST-segment elevation myocardial infarction (NSTEMI), characteristic for the CKD group (28.47%, with statistically significance p = 0.04); unstable angina and myocardial infarction with nonobstructive coronary arteries (MINOCA). Diabetes mellitus, chronic heart failure, previous stroke, and chronic coronary syndrome were more prevalent in the ACS + CKD group (56.93%, p < 0.01; 41.61%, p < 0.01; 18.25%, p < 0.01; 45.26%, p < 0.01). N-terminal pro b-type natriuretic peptide (NT-proBNP) was statistically higher (p < 0.01) in patients with CKD; Killip class 3 was evidenced more frequently in the same group (p < 0.01). Single-vessel coronary artery disease (CAD) was statistically more frequent in the ACS without CKD group (29.41%, p < 0.01) and three-vessel CAD or left main coronary artery disease (LMCA) were found more often in the ACS + CKD group (27.01%, 14.6%). Conclusions: Extension of the CAD in CKD subjects revealed an increased prevalence of the proximal CAD, and the involvement of various coronary arteries is characteristic in these patients. Biomarkers and echocardiographic elements can outline the evolution and outcomes of ACS in CKD patients.
Mădălina Ioana Moisi; Marius Rus; Simona Bungau; Dana Carmen Zaha; Diana Uivarosan; Ovidiu Fratila; Delia Mirela Tit; Laura Endres; Delia Carmen Nistor-Cseppento; Mircea Ioachim Popescu. Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics. Medicina 2020, 56, 118 .
AMA StyleMădălina Ioana Moisi, Marius Rus, Simona Bungau, Dana Carmen Zaha, Diana Uivarosan, Ovidiu Fratila, Delia Mirela Tit, Laura Endres, Delia Carmen Nistor-Cseppento, Mircea Ioachim Popescu. Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics. Medicina. 2020; 56 (3):118.
Chicago/Turabian StyleMădălina Ioana Moisi; Marius Rus; Simona Bungau; Dana Carmen Zaha; Diana Uivarosan; Ovidiu Fratila; Delia Mirela Tit; Laura Endres; Delia Carmen Nistor-Cseppento; Mircea Ioachim Popescu. 2020. "Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics." Medicina 56, no. 3: 118.
Postmenopausal osteoporosis is the most common form of osteoporosis and one of the major public health problems in developed countries. The prevalence of this condition, associated with the physiological stage of menopause, is continuously increasing. This study evaluated the effectiveness of soy isoflavones as compared to hormone replacement therapy (HRT) in low doses, on the prevention of postmenopausal osteoporosis, by determining bone mineral density (BMD) and urinary deoxypyridinoline (D-pyr) in physiological postmenopausal women. The study was conducted over a period of 12 months, on three parallel groups, which included a total of 325 postmenopausal women (HRT group: n = 95; phytoestrogens group: n = 124; control group: n = 106). At the one-year evaluation, we observed T-score normalization in a small number of cases (5.26%, 2.42% and 0.00%, respectively). The average values of D-Pyr decreased by 11.38% in the group treated with phytoestrogens (p < 0.05) and by 15.32% in the group that followed HRT (p < 0.05); it increased by 4.38% in the control group (p > 0.05). Both therapies have beneficial effects on bone metabolism, leading to a significant decrease in the evolution of bone resorption and there are no major differences between the efficacy of HRT and phytoestrogens in terms of the effects on BMD and bone resorption.
Delia Mirela Tit; Simona Bungau; Ciprian Iovan; Delia Carmen Nistor Cseppento; Laura Endres; Cristian Sava; Anca Maria Sabau; Gheorghe Furau; Cristian Furau. Effects of the Hormone Replacement Therapy and of Soy Isoflavones on Bone Resorption in Postmenopause. Journal of Clinical Medicine 2018, 7, 297 .
AMA StyleDelia Mirela Tit, Simona Bungau, Ciprian Iovan, Delia Carmen Nistor Cseppento, Laura Endres, Cristian Sava, Anca Maria Sabau, Gheorghe Furau, Cristian Furau. Effects of the Hormone Replacement Therapy and of Soy Isoflavones on Bone Resorption in Postmenopause. Journal of Clinical Medicine. 2018; 7 (10):297.
Chicago/Turabian StyleDelia Mirela Tit; Simona Bungau; Ciprian Iovan; Delia Carmen Nistor Cseppento; Laura Endres; Cristian Sava; Anca Maria Sabau; Gheorghe Furau; Cristian Furau. 2018. "Effects of the Hormone Replacement Therapy and of Soy Isoflavones on Bone Resorption in Postmenopause." Journal of Clinical Medicine 7, no. 10: 297.
The issue of drug disposal, as well as the development and implementation of efficient collection strategies, represents an important concern at the highest European level. This research looks into the factors that could have an impact on the efficiency of pharmacies in collecting and disposing the medicinal waste of the population. There were 521 pharmacists from all over the country who filled in a questionnaire on their opinion/attitude related to the system of collecting and disposing the pharmaceutical waste of the population. Of the surveyed pharmacists, 16% work in pharmacies that do not collect unused/expired drugs from the population, and nearly 33% of those investigated have refused, at least once, to take the unused medicines from the people. Pharmacists’ most important reasons for refusing to collect the pharmaceutical waste were the lack of procedure, incomplete legislation, exceeding the amount contracted with the operators, and high costs. Results show that pharmacies in Romania face several deficiencies in the pharmaceutical waste collection services. The lack of implemented programs has contributed considerably to lower standards of pharmaceutical waste management in Romania. This study is the first research on this topic in Romania, a country where the management of drug-based waste generated by the population is at the beginning. The results shown in this survey can provide a reference point for competent authorities in developing and implementing a take-back program for waste medicine whose efficiency is superior to the existing ones.
Simona Bungau; Delia Tit; Katalin Fodor; Gabriela Cioca; Maricel Agop; Ciprian Iovan; Delia Cseppento; Adrian Bumbu; Cristiana Bustea. Aspects Regarding the Pharmaceutical Waste Management in Romania. Sustainability 2018, 10, 2788 .
AMA StyleSimona Bungau, Delia Tit, Katalin Fodor, Gabriela Cioca, Maricel Agop, Ciprian Iovan, Delia Cseppento, Adrian Bumbu, Cristiana Bustea. Aspects Regarding the Pharmaceutical Waste Management in Romania. Sustainability. 2018; 10 (8):2788.
Chicago/Turabian StyleSimona Bungau; Delia Tit; Katalin Fodor; Gabriela Cioca; Maricel Agop; Ciprian Iovan; Delia Cseppento; Adrian Bumbu; Cristiana Bustea. 2018. "Aspects Regarding the Pharmaceutical Waste Management in Romania." Sustainability 10, no. 8: 2788.